Welcome to our dedicated page for Assertio Holdings news (Ticker: ASRT), a resource for investors and traders seeking the latest updates and insights on Assertio Holdings stock.
Assertio Holdings Inc (ASRT) is a pharmaceutical innovator specializing in neurology and specialty medicines, offering investors comprehensive news coverage through this dedicated hub. Access real-time updates on FDA-approved therapies, strategic partnerships, and financial developments shaping this dynamic healthcare company.
This resource provides verified press releases and analysis-free announcements covering earnings reports, product launches, and regulatory milestones. Track ASRT's progress in neurology treatments and oncology initiatives like Rolvedon through primary source documentation.
Key updates include acquisition activities, licensing agreements, and commercial strategy developments. Investors gain direct access to the company's official communications regarding market expansion, payor contracting progress, and distribution network enhancements.
Bookmark this page for unfiltered access to Assertio's latest developments in specialty pharmaceuticals. Monitor their focused approach to neurological care and orphan drug commercialization through timely, regulation-compliant disclosures.
Assertio Holdings (Nasdaq: ASRT) has announced its participation in the upcoming iAccess Alpha Best Ideas Spring Investment Conference, scheduled for March 25-26, 2025. CEO Brendan O'Grady will lead the company's presentation on Tuesday, March 25, 2025, at 1:30 pm Eastern Time.
The conference will be held virtually, with a webcast available through the company's investor relations website. Investors attending the conference can schedule one-on-one meetings with Assertio representatives on March 26, 2025, either through their conference representative or by contacting Assertio's investor relations directly.
Assertio Holdings (NASDAQ: ASRT) reported its Q4 and full-year 2024 financial results, with Q4 net product sales of $29.6 million and full-year sales reaching $120.8 million. The company generated strong cash flows, with Q4 operating cash flow of $11.5 million and full-year operating cash flow of $26.4 million.
Q4 highlights include Rolvedon sales of $15.4 million (up $0.4M from Q3) and Indocin sales of $5.5 million (down from $5.7M in Q3). Gross margin was 61% in Q4, down from 74% in Q3, impacted by $2.9 million in inventory write-downs. The company reported an Adjusted EBITDA loss of $0.5 million for Q4.
The company ended 2024 with $100.1 million in cash and investments and $40.0 million in convertible notes debt due September 2027. Management expects 2025 to be transformational, focusing on revenue growth initiatives for Rolvedon and Sympazan while actively pursuing strategic acquisitions.
Assertio Holdings (Nasdaq: ASRT) has scheduled the release of its fourth quarter and full year 2024 financial results on Wednesday, March 12, 2025, after market close. The company will host a live webcast earnings conference call at 4:30 p.m. Eastern Time following the results announcement.
Investors can access the webcast through Assertio's investor relations website, with connection recommended 10 minutes prior to start. For telephone participation, participants should dial +1-646-307-1963 with call ID 3278948. A replay will be available approximately two hours after the call on the company's investor website.
Assertio Holdings (NASDAQ: ASRT) has announced inducement grants for its newly-hired Senior Vice President and Chief Commercial Officer, Mary Pietryga. The compensation package, approved by the Company's Board of Directors' Compensation Committee on December 23, 2024, includes 62,500 restricted stock units (RSUs) and 275,000 stock options.
The stock options have an exercise price of $0.846 per share, matching Assertio's common stock closing price on the grant date. Both RSUs and options will vest equally over three years, starting from the first anniversary of the grant date. These grants were made as inducement materials for employment in accordance with NASDAQ Listing Rule 5635(c)(4).
Assertio Holdings (Nasdaq: ASRT) has appointed Mark Reisenauer as an independent director to its Board of Directors, where he will serve on the Compensation Committee. Reisenauer brings over 30 years of experience in the biopharmaceutical industry, particularly in oncology and hematology. His previous role as President of U.S. Commercial at Astellas Pharmaceuticals saw him grow sales to nearly $5 billion while leading Marketing, Sales, Policy and Government Affairs, and Market Access teams.
The appointment aligns with Assertio's strategy to enhance its commercial platform and explore additional labeling, indication, and channel opportunities for existing products while seeking new commercial assets. Reisenauer's experience includes executive positions at Micromet Inc., Abbott Laboratories, Pharmacia , Bristol-Myers Squibb, and Zeneca Pharmaceuticals.
Assertio Holdings (NASDAQ: ASRT) announced results from a clinical trial evaluating Rolvedon® (eflapegrastim-xnst) injection when administered on the same day as chemotherapy for early stage breast cancer patients. The open-label, single-arm study, conducted across 13 US sites, demonstrated that Rolvedon, when given 30 minutes post-chemotherapy, achieved 1.8 days to neutrophil count recovery with a 2% febrile neutropenia rate. Notably, no patients required hospitalization for febrile neutropenia, and no new safety concerns were identified. The results were presented at the San Antonio Breast Cancer Symposium.
Assertio Holdings (NASDAQ: ASRT) announced key leadership changes with the creation of a new Transformation Office. Paul Schwichtenberg, current Chief Commercial Officer and former CFO, has been appointed as Chief Transformation Officer (CTO). In his previous roles, Schwichtenberg implemented efficiency measures, pricing strategies, and debt refinancing that improved profitability and strengthened the company's balance sheet.
Mary Pietryga will assume the role of Chief Commercial Officer effective December 16, 2024. Pietryga joins from Teva Pharmaceuticals, where she served as VP and Head of Global Biosimilar Portfolio. Her experience includes leadership positions at Peregrine Market Access, Pacira Biosciences, and other major pharmaceutical companies.
The Buxton Helmsley Group (BHG), which recently converted its position in Assertio Holdings (NASDAQ: ASRT) to a short interest, has called for a Senate Committee investigation into alleged clinical data fraud at Spectrum Pharmaceuticals, now owned by Assertio. This request follows the resignation of Assertio's Chairman and oncologist board member, announced shortly after BHG's release of a 20-page exposé. The report cites former executives-turned-whistleblowers who claim to possess evidence of clinical data tampering related to the cancer treatment Rolvedon. BHG criticizes Assertio's CEO Brendan O'Grady's dismissal of the allegations and the company's failure to engage with whistleblowers or review their evidence.
Assertio Holdings (NASDAQ: ASRT) reported Q3 2024 financial results with total net product sales of $28.7 million, including $15.0 million from Rolvedon. The company posted a net loss of $2.9 million, or $(0.03) per share. Rolvedon sales remained stable quarter-over-quarter, while Indocin sales decreased to $5.7 million due to generic competition. The company maintained a strong balance sheet with $88.6 million in cash and short-term investments. Gross margin improved to 74% from 71% in Q2, and Adjusted EBITDA increased to $5.3 million from $5.0 million in the previous quarter.
The Buxton Helmsley Group (BHG), which holds a short position in Assertio Holdings (NASDAQ: ASRT), has released evidence supporting allegations of product-related fraud at Spectrum Pharmaceuticals, now owned by Assertio. The evidence includes a memo showing requests to delete adverse event data and audit reports revealing major discrepancies in clinical trial data. BHG has filed a whistleblower complaint with the SEC and calls on Assertio's board to release their full investigation report and documentation of communication with whistleblowers. BHG claims Assertio's recent denial fails to address specific allegations, including alleged 'hush money' offers to whistleblowers.
